Rectal Indomethacin to Prevent Post ESWL-pancreatitis

• Status: Recruiting
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine whether rectal indomethacin reduces the incidence of post-ESWL pancreatitis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Changhai Hospital
• Treatments: Glycerol; Indomethacin

Criteria

Inclusion Criteria:

• any patient with painful chronic pancreatitis and pancreatic stones (> 5 mm in diameter) undergoing P-ESWL

• at least 18 years old

• provides informed consent

Exclusion Criteria:

• no pain history during course of chronic pancreatitis

• contraindications to ESWL

• suspected or established malignancy

• pancreatic ascites

• receiving NSAIDs within 7 days

• contraindication to NSAIDs (including gastrointestinal hemorrhage within 4 weeks or renal dysfunction with serum creatinine >120 μmol/L)

• presence of coagulopathy or received anticoagulation therapy within 3 days

• acute pancreatitis within 3 days

• known active cardiovascular or cerebrovascular disease

• pregnant or breastfeeding women

• without a rectum (ie, status post-total proctocolectomy)